Monday 19th October 2020 |
Text too small? |
• Second phase of national clinical trial in Sichuan Province reported outstanding results
• Conducted by China Obstetrics and Gynaecology Association (COGA) a peak gynaecology body in China.
• Trial conducted across 14 hospitals with 1,243 patients participating
• Both sensitivity and specificity targeting pre-cancerous and cancerous cervical cells performed in aggregate better than other screening methods (see below table)
Truscreen Group Limited (NZX: TRU ) (Truscreen or Company) is pleased to advise results from The China Obstetrics and Gynaecology Association (COGA) ongoing national clinical trial that will screen over 20,000 women in 100 top-tier public hospitals across 10 provinces in China. The COGA evaluation compares the TruScreen technology to Liquid Based Cytology (LBC), and HPV DNA testing (HPV) and targets a nationwide consensus on Truscreen technology application in China as the main outcome of this large-scale trial.
See the link below for more details:
Sichuan Province Trial Confirms Truscreen Technology
Source: Truscreen Group Limited
No comments yet
TGG - Response to media speculation
ARB - Annual Meeting Date and Director Nominations
CNU - Q4 FY25 Connections Update
MOVE FY25 Results and Investor Briefing 29 August 2025
RYM - First quarter trading update
July 11th Morning Report
IKE Announces equity raising of A$20 million
Chorus full year results date
FPH 2025 Notice of Annual Meeting and Voting Form
July 10th Morning Report